Picture of Vetoquinol SA logo

VETO — Vetoquinol SA Share Price

0.000.00%
fr flag iconLast trade - 00:00
HealthcareBalancedMid CapHigh Flyer

Momentum

Relative Strength (%)
1m-8.35%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w High-18.01%
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Financial Summary

Year End 31st DecUnit201620172018201920202021E2022ECAGR / Avg
Total Revenue€m350.35352.17367.94395.99427.47523.88556.14.52%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+7.98+18.96+4.32-11.37-8.86+107.04+3.23n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for VETO

Two factors to watch at Vetoquinol Sa background image

Two factors to watch at Vetoquinol Sa

Shares in Vetoquinol Sa (EPA:VETO) are currently trading at 92 but a key question for investors is how the economic uncertainty caused by Covid-19 will affect the price in the months to come. The answer comes down to judging whether Ve...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Vetoquinol SA EPS forecast chart

Profile Summary

Vetoquinol SA is a France-based company that specializes in the research, development, manufacture, marketing and sale of veterinary drugs and products. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The Company markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. It trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.

Directors

Last Annual
December 31st, 2020
Last Interim
June 30th, 2021
Incorporated
January 1st, 1962
Public Since
November 16th, 2006
No. of Employees
2,400
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
fr flag iconEuronext - Paris
Shares in Issue
11,828,662

VETO Share Price Performance

Similar to VETO

Picture of AB Science SA logo

AB Science SA

fr flag iconEuronext - Paris

Picture of Advicenne SA logo

Advicenne SA

fr flag iconEuronext - Paris

Picture of Biocorp Production SA logo

Biocorp Production SA

fr flag iconEuronext - Paris

Picture of Boiron SA logo

Boiron SA

fr flag iconEuronext - Paris

Picture of DBV Technologies SA logo

DBV Technologies SA

fr flag iconEuronext - Paris

FAQ

Or unlock with your email

Or unlock with your email